Jonathan Silverberg, MD, PhD, MPH, Director of Clinical Research at The George Washington University School of Medicine and Health Sciences in Washington, DC, breaks down the new data from LEVEL-UP, a head-to-head study evaluating upadacitinib (Rinvoq, AbbVie) vs. dupilumab (Dupixent, Sanofi & Regeneron) for the treatment of adolescents and adults with moderate to severe atopic dermatitis who had inadequate response to systemic therapy or when systemic therapies were not advised. The late-breaking data, presented at the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, IL, showed that upadacitinib bested dupilumab for all ranked secondary endpoints of LEVEL-UP, including complete skin clearance and rapid resolution of itching in patients with severe itch.
